Our main axes

A three-axes strategic approach to support drug development processes

Central Lab Services

A Unique Technology Partner and Cancer Biology Integrator for Clinical Trials

  • From single gene to complete panel – DNA/RNA
  • Using solid tumor (FFPE block or slides) and/or liquid biopsy (blood, urine, CSF, saliva, …)
  • Combined with Molecular Pathology tools: IHCs, FISH, CISH
  • From sample to biological and clinical interpretation
  • AND the most flexible and personalized ctDNA solution

From Data to Knowledge

OncoKDM: A unique data interpretation and integration, customizable interface linked to our expertise

  • Integrative: DNA (Ion Torrent, Illumina,…), RNA (microarray, transcriptome), protein (IHC, MS,…)
  • QC of third party data sets and biomarker calling
  • Centralization: a unique, secure and robust web portal giving access to data and interpretation to every eligible partner

Precision Enrollment

A new way to bring together fully characterized patients and biopharma together in a mutually beneficial clinical trial

Every day, OncoDNA characterizes patients from all over the world… Most of our conclusions/reports are listing FDA or EMA approved treatments. But in some cases, the best or only treatment options left are compounds which are still under clinical development. So, some patients are in desperate need to get access to these clinical trial...

More

Applications

Applications are numerous and varied:

NGS or IHC biomarker discovery, validation and clinical testing

Utilizing the existing OncoDNA gene panels (from 65 to 409 genes) and molecular pathology panels (in a catalog of more than 100 IHCs, FISH,…) or starting from data generated by third parties (WES, WGS,…).

Patient stratification and targeted enrollment

Testing the expression of a drug target, searching for the presence of an activating mutation or combining NGS and IHC to confirm the presence and/or activity of a key marker at DNA and protein level.

Drug response monitoring using liquid biopsy

Measuring and analyzing ctDNA in liquid biopsy (blood, urine, CSF, saliva,…) to monitor candidate treatment response.

Pan-cancer and Pan-technology CDx development, validation and testing

Any combination of genes, alterations, genomic characteristics and/or molecular pathology biomarker can be developed for partners as a clinical trial assay (CTA) .

Data mining and clinical data integration for special responder characterization

Patterns search using clinical and real world data, OncoKDM database system and proprietary algorithm, machine learning approach,…

Mechanism of Action and Mechanism of Resistance elucidation

Accelerated using ctDNA monitoring and combining genomic and proteomic tools coupled with data to knowledge approach of OncoKDO.

New therapeutic indication exploration

Based on molecular characterization of the disease, on of label follow-up data in our database and on real or virtual basket trial results.

Many more to come…

A new way to bring together fully characterized patients and biopharma together in a mutually beneficial clinical trial

Every day, OncoDNA characterizes patients from all over the world… Most of our conclusions/reports are listing FDA or EMA approved treatments. But in some cases, the best or only treatment options left are compounds which are still under clinical development. So, some patients are in desperate need to get access to these clinical trial.

The other way around, they are more and more biopharmas involved in cancer treatment development, which happily means more and more compounds being tested in clinical trials and more and more patients needed to complete these clinical trials. Also, as many of those compounds are targeting specific molecular events, eligible patients are more and more specific and difficult to find.

Our job ? Help both patients and biopharma with targeted recruitment fitting clinical trial design and needs. Our program leans on the fast growing number of patients and oncologists using OncoDEEP, OncoSTRAT&GO and OncoTRACE and on our OncoSHARE and OncoKDM databases.

Part of Our Expert Team

Working with OncoDNA means having access to a team of more than 50 people in IT, bioinformatics and a lab (IPG) of more than 250 people treating tumor samples daily.

Get In Touch

Leave A Comment